The Food and Drug Administration last week authorized the emergency use of a third diagnostic test that detects and differentiates flu and COVID-19 viruses from one another. 

The test from the Centers for Disease Control and Prevention, along with previously authorized tests from BioFire Diagnostics LLC and QIAGEN GmbH, require only a single sample from patients who exhibit respiratory disease symptoms. FDA said these tests will use fewer supplies and provide faster and comprehensive results.

Related News Articles

Headline
Adam Myers, M.D., population health chief at Cleveland Clinic, talks with Nancy Foster, AHA vice president for quality and patient safety, about preventing flu…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…
Headline
In a study of 106,543 patients hospitalized for COVID-19 between March and July, 9% were readmitted to the same hospital within two months of discharge, the…
Headline
The Centers for Medicare & Medicaid Services last week launched the Nursing Home Resource Center to provide the latest COVID-19 information, guidance and…
Blog
For the last several months, disturbing and unproven theories have gained attention about the death count for COVID-19. We find these erroneous and egregious…
Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…